Comparative Pharmacology
Head-to-head clinical analysis: PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE versus QUDEXY XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE versus QUDEXY XR.
PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE vs QUDEXY XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phentermine is a sympathomimetic amine that stimulates norepinephrine release in the hypothalamus, reducing appetite. Topiramate modulates GABA-A receptors, inhibits AMPA/kainate glutamate receptors, and inhibits carbonic anhydrase, enhancing satiety and reducing cravings.
Stabilizes neuronal membranes and inhibits repetitive firing of action potentials via blockade of voltage-gated sodium channels; also enhances GABAergic activity and inhibits glutamate release.
Oral: Initial 3.75 mg phentermine / 23 mg topiramate once daily for 14 days, then increase to 7.5 mg/46 mg once daily. If <3% weight loss after 12 weeks, discontinue or escalate to 15 mg/92 mg once daily.
Initial dose 25 mg orally twice daily; titrate by 25-50 mg/day every 1-2 weeks to target dose of 200-400 mg/day in two divided doses. Maximum 400 mg/day.
None Documented
None Documented
Phentermine: 20-25 hours (terminal); Topiramate: 19-23 hours (healthy adults), prolonged in renal impairment (up to 35 hours). Clinical context: Steady state reached in 4-5 days; supports once-daily dosing.
Terminal elimination half-life is approximately 70-90 hours after multiple dosing, supporting twice-daily dosing; requires slow titration to steady state (2-3 weeks).
Phentermine: Renal (80% unchanged, 20% as metabolites). Topiramate: Renal (70% unchanged, 30% metabolized). Total dose eliminated renally: >90% combined.
Renal: approximately 70% as unchanged drug; fecal: approximately 20%; biliary: minor (<5%).
Category C
Category C
Anticonvulsant
Anticonvulsant